Setmelanotide 2 mg + Setmelanotide 2.5 mg + Setmelanotide 3 mg + Setmelanotide 20 mg + Setmelanotide 25 mg + Setmelanotide 30 mg
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bardet-Biedl Syndrome
Conditions
Bardet-Biedl Syndrome, POMC Deficiency
Trial Timeline
Dec 21, 2021 → Oct 19, 2023
NCT ID
NCT05194124About Setmelanotide 2 mg + Setmelanotide 2.5 mg + Setmelanotide 3 mg + Setmelanotide 20 mg + Setmelanotide 25 mg + Setmelanotide 30 mg
Setmelanotide 2 mg + Setmelanotide 2.5 mg + Setmelanotide 3 mg + Setmelanotide 20 mg + Setmelanotide 25 mg + Setmelanotide 30 mg is a phase 3 stage product being developed by Rhythm Pharmaceuticals for Bardet-Biedl Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT05194124. Target conditions include Bardet-Biedl Syndrome, POMC Deficiency.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05194124 | Phase 3 | Completed |
Competing Products
2 competing products in Bardet-Biedl Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Setmelanotide | Rhythm Pharmaceuticals | Phase 3 | 74 |
| Setmelanotide, administered subcutaneously [SC], once daily. | Rhythm Pharmaceuticals | Pre-clinical | 20 |